- The trend backdrop is active with a 7-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
AHCL
NSI
Week ended 07 Aug 2026
Weekly Investor Report
ANLON HEALTHCARE LIMITED · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
14.55 INR
-0.4%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 6.9% above the Trend Line and sits at 66.8% of its 52-week range. The latest completed week returned -0.4%, after a -6.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal.
Setup score
41
out of 100
Latest Close
14.55 INR
7 Aug 2026
1W Return
-0.4%
latest completed week
4W Return
-6.7%
short-term follow-through
12W Return
9.0%
quarterly tape
Trend Breadth
14.3%
7 of 49 weeks active
Volume Ratio
0.8x
vs 13-week average
- Next-week expectancy is negative at 40.30% based on similar historical setup states.
- 2 reversal markers appear in the recent smart-money tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.4%
Latest completed week; four-week move -6.7%.
Indicator stack
32/44
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 40.30%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
54/100
43 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 6.9% above the Trend Line and sits at 66.8% of its 52-week range. The latest completed week returned -0.4%, after a -6.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7112-week average 0.58
12-week confirmation
Trend active7/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.71Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -6.7% over four weeks, 9.0% over 12 weeks, and - over one year. The current trend has remained active for 7 consecutive weeks.
Performance by holding period
Active trend streak7 weeks
Active weeks in one year7
Trend breadth14.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.08Latest activity-pressure read.
Pressure change-90.5%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 82%
Model confidence 77%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength49/100Blend of value, momentum, and quality. Underlying universe rank 52; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality30/100Profitability and accounting quality. Underlying universe rank 71; rank 1 is best.
Momentum44/100Medium-term price momentum. Underlying universe rank 57; rank 1 is best.
Growth92/100Revenue and earnings growth. Underlying universe rank 9; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework64/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 27.1x Price divided by trailing earnings.
- Price / sales
- 4.5x Market value relative to trailing revenue.
- EV / EBITDA
- 0.6x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -13.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 38.9% Gross profit retained from each unit of revenue.
- Operating margin
- 26.8% Operating profit retained from revenue.
- Free-cash-flow margin
- -67.4% Free cash flow generated from revenue.
- Return on invested capital
- 12.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 43.0% Latest one-year revenue growth.
- EPS growth
- 39.0% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -15.7% Net share repurchases relative to market value.
- Shareholder yield
- -15.7% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 43 relevant articles.
12 positive · 29 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-15.8%Distance below the 52-week high.
13-week volatility4.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher11 of 2615 weeks finished lower.
Best week+14.8%Week of 10 Apr.
Worst week-16.2%Week of 1 May.
Latest week-0.4%Week of 7 Aug.
Shape of recent returns
Strong gains9
Modest gains2
Flat weeks0
Modest losses10
Sharp losses5
Recent vol4.1%13-week weekly-return volatility.
Base vol7.4%52-week weekly-return volatility.
Up/down split22/26Count of positive and negative weeks in the 52-week window.
Average skew7.6% / -4.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank73 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape40/100
Trend, activity pressure, participation, and risk combine to a 40/100 tape read.
Indicator analysis53/100Latest 12-week confirmation: trend 7/12, activity pressure 12/12, relative leadership 0/12.
Activity pressure 0.71; 2 reversal markers Next-Week ExpectancyNegative 40.30%Next-week expectancy is negative with a 40.30% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors45/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 96; Small Cap Core rank 62 SVQF64/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 570.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 43 relevant articles.
Anlon Healthcare Q1 Results: Earnings call scheduled for Aug 6 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 14.55 INR | -0.4% | 13.61 INR | 13.59 INR | 0.08 | - | 10.4M | On |
| 31 Jul 2026 | 14.61 INR | -2.7% | 13.60 INR | 13.57 INR | 0.34 | - | 39.5M | On |
| 24 Jul 2026 | 15.01 INR | 1.9% | 13.62 INR | 13.55 INR | 0.51 | - | 15.0M | On |
| 17 Jul 2026 | 14.73 INR | -5.5% | 13.61 INR | 13.52 INR | 0.66 | - | 13.4M | On |
| 10 Jul 2026 | 15.59 INR | -1.8% | 13.58 INR | 13.49 INR | 0.82 | - | 18.4M | On |
| 3 Jul 2026 | 15.87 INR | -2.6% | 13.53 INR | 13.44 INR | 0.77 | - | 13.1M | On |
| 26 Jun 2026 | 16.29 INR | -0.1% | 13.50 INR | 13.38 INR | 0.68 | - | 0 | On |
| 19 Jun 2026 | 16.30 INR | 8.2% | 13.51 INR | 13.32 INR | 0.60 | - | 6.6M | Off |
| 12 Jun 2026 | 15.06 INR | 7.7% | 13.49 INR | 13.24 INR | 0.51 | - | 10.5M | Off |
| 5 Jun 2026 | 13.98 INR | 0.9% | 13.46 INR | 13.20 INR | 0.44 | - | 5.1M | Off |
| 29 May 2026 | 13.85 INR | -0.4% | 13.46 INR | 13.18 INR | 0.47 | - | 15.6M | Off |
| 22 May 2026 | 13.91 INR | 4.2% | 13.43 INR | 13.16 INR | 0.48 | - | 8.6M | Off |
| 15 May 2026 | 13.35 INR | -5.2% | 13.38 INR | 13.14 INR | 0.60 | - | 12.5M | Off |
| 8 May 2026 | 14.08 INR | 5.9% | 13.36 INR | 13.13 INR | 0.66 | - | 13.5M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.